RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point


ERGÜL M. , Bakar-Ates F.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.19, no.15, pp.1846-1854, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 15
  • Publication Date: 2019
  • Doi Number: 10.2174/1871520619666190618162828
  • Title of Journal : ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Page Numbers: pp.1846-1854

Abstract

Background: As a member of serine/threonine-protein kinase, Polo-like kinase 1 (PLK1) plays crucial roles during mitosis and also contributes to DNA damage response and repair. PLK1 is aberrantly expressed in many types of tumor cells and increased levels of PLK1 are closely related to tumorigenesis and poor clinical outcomes. Therefore, PLK1 is accepted as one of the potential targets for the discovery of novel anticancer agents. The objective of this study was to assess the cytotoxic effects of a novel PLK1 inhibitor, RO3280, against MCF-7, human breast cancer cells; HepG2, human hepatocellular carcinoma cells; and PC3, human prostate cancer cells, as well as non-cancerous L929 fibroblast cells.